Takeda Pharmaceutical has delivered additional data on the sustained efficacy of its hereditary angioedema (HAE) treatment Takhzyro (lanadelumab) in reducing HAE attacks, with a follow-up of up to 2.5 years showing results consistent with the initial period of treatment. Takeda…
To read the full story
Related Article
- Takeda Seeks Japan Approval for HAE Med Lanadelumab
March 15, 2021
- Takhzyro Shows Sustained Effect in Staving Off HAE Attacks
June 9, 2020
BUSINESS
- TS Alfresa-Backed Drone Council Inks Pact with Hiroshima
October 19, 2026
- Santen to Seek Bankruptcy for Chinese Subsidiary
October 19, 2026
- Toho Invests in Keio Offshoot AdipoSeeds
October 19, 2026
- Amgen, JASSO Team Up on Obesity Research and Care
October 19, 2026
- Sanwa Kagaku to Resume Kumamoto Production on October 19
October 19, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…





